A Pharmacogenetic Investigation of Antipsychotics in Schizophrenia and Schizophrenia-Like Psychoses
NCT00701753 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 24
Last updated 2009-03-12
Summary
An individual's genetic make-up is known to determine their response to antipsychotic medication. Genetic markers that determine efficacy and side effects of medication may be identified and used to predict treatment outcome.
The study is a naturalistic study of routinely prescribed antipsychotics using outcome measures undertaken as part of the routine clinical care of the cohort. These clinical data are linked with genetic information obtained from DNA and RNA from blood samples undertaken as part of the study.
No alteration is made to the subjects treatment regime or medication.
The study is a two stage investigation:
* The first stage involves the collection of a databank of clinical information and blood samples for DNA and RNA extraction from patients treated with antipsychotic medication.
* The second stage is a molecular genetic investigation of treatment-related genetic factors that may contribute to response prediction and predisposition to side effects.
From these genetic studies pharmacogenetic prediction tests will be validated and/or developed.
Conditions
- Schizophrenia
- Schizoaffective Disorder
Sponsors & Collaborators
-
TheraGenetics Limited
lead INDUSTRY
Principal Investigators
-
Soma Ganesan, MD · Vancouver Coastal Health
-
Janet Munro, MB BS · TheraGenetics Limited
Eligibility
- Min Age
- 19 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-05-31
- Primary Completion
- 2009-03-31
- Completion
- 2009-03-31
Countries
- Canada
Study Locations
More Related Trials
-
Novel Candidate Genes for Treatment Response to Antipsychotics in Schizophrenia
NCT02205437 ·Status: UNKNOWN
-
Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis
NCT02566057 ·Status: COMPLETED ·Phase: NA
-
Genetics of Schizophrenia
NCT00619437 ·Status: UNKNOWN
-
Pharmacogenomic and Pharmacoepigenomic Studies of Antipsychotic Drugs in First-Episode Schizophrenia
NCT07102069 ·Status: COMPLETED
-
Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment With Antipsychotics
NCT02573168 ·Status: COMPLETED ·Phase: NA
-
Genetics of Symptomatology and Treatment Response in Psychotic Major Depression
NCT00691535 ·Status: COMPLETED
-
Phenomics and Genomics of Clozapine Pharmacotherapy
NCT03253367 ·Status: UNKNOWN
-
5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia
NCT02435654 ·Status: COMPLETED ·Phase: PHASE4
-
Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting
NCT00932529 ·Status: COMPLETED ·Phase: PHASE4
-
Genes Polymorphisms and Metabolic Effects of the Second Generation Antipsychotic Drugs in Patients With Schizophrenia
NCT02964923 ·Status: UNKNOWN
-
A Neurobiological Study on Heterogeneity of Schizophrenia: Genetic Variations and Neurobiological Differentiations
NCT01075373 ·Status: UNKNOWN
-
Quality of Life in Schizophrenic Patients
NCT00597168 ·Status: COMPLETED
-
Genetic Study of Schizophrenia
NCT00001486 ·Status: COMPLETED
-
Gabapentin in Patients at Clinical Risk for Psychosis
NCT02557945 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia
NCT00001198 ·Status: TERMINATED
-
Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm
NCT01016145 ·Status: UNKNOWN ·Phase: PHASE4
-
Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia
NCT00669903 ·Status: TERMINATED ·Phase: PHASE2
-
The Genetic Basis of Inherited Neurologic Deficits in People With Schizophrenia
NCT00247637 ·Status: COMPLETED
-
Schizophrenia and Genetic Counseling
NCT00111202 ·Status: UNKNOWN
-
Relationship Between Neurotransmitter Receptor Polymorphisms, Plasma Concentrations and Clinical Response to Clozapine
NCT00581932 ·Status: COMPLETED
-
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
NCT00570063 ·Status: TERMINATED ·Phase: PHASE2
-
Association of Multiple Genetic Polymorphisms With Clozapine-Associated Metabolic Change in Schizophrenia
NCT00717509 ·Status: UNKNOWN
-
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
NCT01269710 ·Status: COMPLETED
-
Translational Investigation of the Glutamatergic and GABAergic System in Schizophrenia
NCT04655235 ·Status: RECRUITING
-
Investigation of Neurophysiological Markers, Possibly Specific of Two Subforms of Psychotic Disorders
NCT03649581 ·Status: RECRUITING ·Phase: NA